264 related articles for article (PubMed ID: 36942976)
1. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
[TBL] [Abstract][Full Text] [Related]
2. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
[TBL] [Abstract][Full Text] [Related]
3. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.
Li R; Liu H; Fairley CK; Zou Z; Xie L; Li X; Shen M; Li Y; Zhang L
Int J Infect Dis; 2022 Jun; 119():87-94. PubMed ID: 35338008
[TBL] [Abstract][Full Text] [Related]
5. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
Kohli MA; Maschio M; Joshi K; Lee A; Fust K; Beck E; Van de Velde N; Weinstein MC
J Med Econ; 2023; 26(1):1532-1545. PubMed ID: 37961887
[TBL] [Abstract][Full Text] [Related]
6. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan.
Nagano M; Kamei K; Matsuda H; Takahashi C; Yang J; Wada K; Yonemoto N
Expert Rev Vaccines; 2024; 23(1):349-361. PubMed ID: 38411109
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.
Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Meijerink H; Ljung R; Hviid A
BMJ; 2023 Jul; 382():e075286. PubMed ID: 37491022
[TBL] [Abstract][Full Text] [Related]
9. Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand.
Thakkar K; Spinardi J; Kyaw MH; Yang J; Mendoza CF; Ozbilgili E; Dodd J; Yarnoff B; Punrin S
Expert Rev Vaccines; 2023; 22(1):860-870. PubMed ID: 37779484
[TBL] [Abstract][Full Text] [Related]
10. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
[TBL] [Abstract][Full Text] [Related]
11. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
12. Modeling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Malaysia.
Thakkar K; Spinardi J; Kyaw MH; Yang J; Mendoza CF; Dass M; Law W; Ozbilgili E; Yarnoff B
Expert Rev Vaccines; 2023; 22(1):714-725. PubMed ID: 37548520
[TBL] [Abstract][Full Text] [Related]
13. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
Kohli M; Maschio M; Becker D; Weinstein MC
Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
[TBL] [Abstract][Full Text] [Related]
14. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
Auvigne V; Tamandjou Tchuem CR; Schaeffer J; Vaux S; Parent Du Chatelet I
Vaccine; 2023 Aug; 41(38):5490-5493. PubMed ID: 37541823
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England.
Kirsebom FCM; Andrews N; Stowe J; Dabrera G; Ramsay M; Lopez Bernal J
EClinicalMedicine; 2024 May; 71():102587. PubMed ID: 38618208
[TBL] [Abstract][Full Text] [Related]
17. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
[TBL] [Abstract][Full Text] [Related]
18. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan.
Fust K; Joshi K; Beck E; Maschio M; Kohli M; Lee A; Hagiwara Y; Van de Velde N; Igarashi A
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675816
[TBL] [Abstract][Full Text] [Related]
19. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
